Amgen Inc. · NASDAQ:AMGN
Amgen — Q3 2026 Earnings Presentation
28 slides from Amgen's earnings presentation, Nov 3, 2026
Slide 1: Q3 2026 Earnings Call
Q3 2026 Earnings Call NOVEMBER 3, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outco
Slide 3: Q3 2026 Financial Highlights and Six Key Growth Drivers
Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the Robert A. Bradway enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late- Chairman and CEO stage pipeline, reinforces our
Slide 4: Commercial Update
Commercial Update Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 4
Slide 5: Broad-Based Growth Continued Across Our Portfolio in Q3 2026
Broad-Based Growth Continued Across Our Portfolio in Q3 2026 8% Total Revenue Growth 17 Products with at least double-digit sales growth 17 Products are annualizing at $1B+ based on Q3 sales Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking sta
Slide 6: Six Key Growth Drivers Grew 27% YoY
Six Key Growth Drivers Grew 27% YoY, Representing More than 70% of Q3 Product Sales, Demonstrating Broad Portfolio Growth $1.1B $0.8B $0.5B $9.9B Product Sales Q3 ’26 Innovative Rare Disease Biosimilars +8% YoY Oncology* $1.6B $2.1B $1.0B *Innovative Oncology includes Blincyto®, Imdelltra®, Kyprolis
Slide 7: Repatha, EVENITY, and TEZSPIRE Expanding Treatment Options
Repatha®, EVENITY®, and TEZSPIRE® Are Expanding Treatment Options in Large, Underserved Markets +37% * +39% * +43% * Reaching more patients across Helping address fracture risk Broadening treatment options primary care and cardiology through a bone-building-first across severe asthma and approach CR
Slide 8: Rare Disease, Innovative Oncology, and Biosimilars Continue to Drive Growth
Rare Disease, Innovative Oncology, and Biosimilars Continue to Drive Broad Portfolio Growth INNOVATIVE RARE DISEASE BIOSIMILARS ONCOLOGY** +21% * +21%* +26% * UPLIZNA® is bringing a differentiated IMDELLTRA® demonstrated positive PAVBLU® adoption building treatment option to patients across overall
Slide 9: R&D Update
R& D Update AMGEN
Slide 10: Accelerating Science to Fight the World's Toughest Diseases
Accelerating Science to Fight the World’s Toughest Diseases THERAPEUTIC AREAS MODALITIES AI & DATA General Medicine | Rare Disease Small Molecules | siRNA | Biologics Accelerating Discovery & Development Inflammation | Oncology with AI at Scale siRNA = small interfering ribonucleic acid; AI = artifi
Slide 11: Phase 3 Pipeline with Breadth and Depth Across All Four Therapeutic Areas
Phase 3 Pipeline with Breadth and Depth Across All Four Therapeutic Areas Pursuing Novel Innovative Molecules and Late-Stage Expansions in Phase 3 Studies MariTide (Chronic weight UPLIZNA® (Autoimmune hepatitis) BLINCYTO® (B-ALL) ABP 206 management) (Investigational biosimilar to UPLIZNA® (Primary M
Slide 12: 2026 is a Year of Disciplined Data Generation
2026 is a Year of Disciplined Data Generation 43K IMDELLTRA® Presented positive overall survival benefit in 1L maintenance in ES-SCLC from Ph3 DeLLphi-305 study with IMDELLTRA + IMFINZI® vs. IMFINZI® alone at ESMO PATIENTS ON STUDY Approved for reduced monitoring of 6-8 hours for the first two d
Slide 13: Anticipated Milestones in 2026
Anticipated Milestones in 2026 STUDY INITIATIONS STUDY COMPLETIONS MAJOR APPROVALS ✓ MARITIDE ✓ TEPEZZA® ✓ UPLIZNA® ✓ ✓ Phase 3 Switching from weekly Phase 3 on-body injector ✓ Generalized myasthenia gravis GLP-1 therapies (OBI) in H1 (gMG) in EU MARITIDE Dazodalibep IMDELLTRA® Phase 3 CWM maintenan
Slide 14: Key Data Presented in Q3 2026
Key Data Presented in Q3 2026 IMDELLTRA® in 1L Maintenance ES-SCLC IMDELLTRA® in 1L Maintenance ES-SCLC Phase 3 DeLLphi-305 Phase 1b DeLLphi-303 long-term follow up Scan this QR code to download the poster IMDELLTRA® in 2L ES-SCLC Phase 3 DeLLphi-304 long-term follow up Scan this QR code to download
Slide 15: Key Data Presented in Q3 2026
Key Data Presented in Q3 2026 TEZSPIRE® in Eosinophilic Esophagitis Daxdilimab in DLE Phase 3 CROSSING Phase 2 Study Scan this QR code to Materials can be accessed at download the https://congressdata.amgenmedinfo.com presentation DLE = discoid lupus erythematosus Copies of the materials obtained th
Slide 16: Financial Update
Financial Update Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 16
Slide 17: Q3 2026 Financials Reflect Strong Execution
Q3 2026 Financials Reflect Strong Execution Total Revenues R&D Investment** Earnings Per Share** $10.4B $2.1B $6.45 +8%* +11%* +14%* Operating Margin** Free Cash Flow** Capital Expenditures (% of product sales) 47% $3.7B $0.6B R&D Investments** of $2.1B increased 11% YoY with an operating margin** o
Slide 18: Q3 2026 Non-GAAP Financials Reflect Strong Execution
Q3 2026 Non-GAAP Financials Reflect Strong Execution $ Billions, Except Non-GAAP EPS Q3 ’26 Q3 ’25 % Inc/(Decr) Revenues $10.4 $9.6 8% Product Sales $9.9 $9.1 8% Other Revenues 0.5 0.4 15% Operating Expenses 5.7 5.3 8% Operating Income 4.7 4.3 9% % of product sales 47.3% 47.1% Net Income 3.5 3.1 15%
Slide 19: Cash Flow and Balance Sheet Data as of Q3 '26
Cash Flow and Balance Sheet Data as of Q3 ’26 $ Billions, Except Dividends Paid Per Share Cash Flow Data Q3 ’26 Q3 ’25 Capital Expenditures $0.6 $0.4 Depreciation $0.2 $0.2 Intangible Asset Amortization $0.9 $1.1 Free Cash Flow* $3.7 $4.2 Share Repurchases $0.0 $0.0 YoY Dividend Increase 6% 6% Divid
Slide 20: 2026 Guidance
2026 Guidance Current Guidance Previous Guidance Revenues $38.9B – $39.7B $38.2 – $39.4B Non-GAAP EPS* $22.90 – $23.70 $22.30 – $23.50 Non-GAAP Tax Rate* 15.0% – 16.5% 15.0% – 16.5% Capital Expenditures ~$2.6B ~$2.6B *Non-GAAP financial measure—if this slide is in hard copy, see reconciliations acco
Slide 21: Q&A
Q&A Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 21
Slide 22: Reconciliations
Reconciliations Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 22
Slide 23: Consolidated Statements of Income - GAAP
Amgen Inc. Consolidated Statements of Income - GAAP (In millions, except per - share data) (Unaudited) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Revenues: Product sales $ 9,883 $ 9,137 $ 27,638 $ 25,781 Other revenues 482 420 1,399 1,104 Total revenues 10,3
Slide 24: Consolidated Balance Sheets - GAAP
Amgen Inc. Consolidated Balance Sheets - GAAP (In millions) September 30, December 31, 2026 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $ 13,190 $ 9,129 Trade receivables, net 10,353 9,570 Inventories 6,389 6,225 Other current assets 4,431 4,133 Total current assets 34,363 29,0
Slide 25: GAAP to Non-GAAP Reconciliations
Amgen Inc. GAAP to Non-GAAP Reconciliations (Dollars In millions) (Unaudited) 25 Provided Nov. 3, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 25
Slide 26: GAAP to Non-GAAP Reconciliations (EPS)
Amgen Inc. GAAP to Non-GAAP Reconciliations (In millions, except per-share data) (Unaudited) (Continued from previous slide) The following table presents the computations for GAAP and non-GAAP diluted earnings per share: Three months ended Three months ended September 30, 2026 September 30, 2025 GAA
Slide 27: Reconciliations of Cash Flows
Amgen Inc. Reconciliations of Cash Flows (In millions) (Unaudited) Three months ended Nine months ended September 30, September 30, 2026 2025 2026 2025 Net cash provided by operating activities $ 4,241 $ 4,684 $ 10,432 $ 8,355 Net cash used in investing activities (649) (414) (1,934) (1,250) Net cas
Slide 28: Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance
Amgen Inc. Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP diluted EPS guidance $18.34 — $19.28 Known adjustments to arrive at non-GAAP*: Acquisition-related expenses (a) 5.99 — 6.13 Net gains from equity investments (1.70) Other 0.